{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T07:59:39Z","timestamp":1781078379085,"version":"3.54.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Bursa Uludag University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mycopathologia"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Mucormycosis ranks third among invasive mycoses after Candidiasis and Aspergillosis and is associated with high mortality. Its incidence has increased with the rising number of immunosuppressed patients. In developing countries, the most common predisposing factor is uncontrolled diabetes mellitus (DM), whereas in developed countries it is immunosuppressive conditions. To examine local epidemiological data, predisposing factors, diagnostic and therapeutic options and survival in our center eighty-six adult mucormycosis patients between 2000 and 2020 were retrospectively analyzed. Thirty-nine (45.35%) were male, 47 (54.65%) were female, and the median age was 52\u00a0years (IQR, 42.5\u201362). The most frequent clinical presentation was sinus involvement, observed in 77 cases (89.53%). Of these, 38 (44.18%) were sinonasal, 5 (5.81%) sinoorbital, 9 (10.47%) rhinocerebral, and 25 (29.07%) rhino-orbito-cerebral mucormycosis. The remaining 9 cases (10.47%) had pulmonary mucormycosis. Predisposing factors included hematologic diseases in 51 patients (59.30%), DM in 33 (38.37%), solid organ transplantation (SOT) in 7 (8.14%), and solid organ malignancy in 7 (8.14%). The most common symptoms were fever (70.93%), swelling around the eyes and face (51.16%), pain (40.7%), erythema (34.88%), nasal discharge (30.23%), and headache (25.58%). Most frequent physical examination findings were necrotic lesions in the oral cavity and sinuses (87.21%), ophthalmoplegia (29.07%), ptosis (26.74%), vision loss (25.58%), and proptosis (22.09%). In all cases, amphotericin B formulations were preferred as initial therapy. Patients who received combination therapy (n\u2009=\u200914), 13 used posaconazole (POS)\u2009+\u2009liposomal amphotericin B (L-AmB) and one patient used itraconazole (ITC)\u2009+\u2009L-AmB. POS was administered to 14 patients receiving sequential oral therapy. The median duration of amphotericin B therapy was 46.5\u00a0days (IQR, 14.7\u201384.5), and the median total duration of antifungal therapy was 46.5\u00a0days (IQR, 14.7\u201390.3). The most common adverse effect of amphotericin B formulations was hypokalemia [L-AmB 68.75%, amphotericin B deoxycholate (AmB-D) 54.84%, amphotericin B lipid complex (ABLC) 50%]. At least one surgical intervention was performed in 74.42% of cases. The 12-week mortality rate was 48.84%, overall mortality rate was 61.63%. In analysis advanced age [12-week: OR: 1.04 (95% CI: 1.01\u20131.07),\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.011; overall: OR: 1.04 (95% CI: 1.01\u20131.07),\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.026 respectively], coexistence of both hematologic disease and DM [12-week OR: 5.73 (95% CI: 1.16\u201328.33),\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.032] associated with mortality. No significant difference was observed in 12-week mortality between surgical and non-surgical patients (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.107). In contrast, overall mortality was significantly higher in the non-surgical group (81.8% vs. 54.7%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.024). In univariable logistic regression analysis, surgical intervention was associated with a 73.2% reduction in the odds of overall mortality (OR: 0.268, 95% CI: 0.082\u20130.882,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.030). In the multivariable logistic regression analysis, age was the only variable significantly associated with 12-week and overall mortality (respectively,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.004 and\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.026). Each one-year increase in age was associated with an OR of 1.05 (95% CI: 1.02\u20131.09) for 12-week mortality and 1.04 (95% CI: 1.01\u20131.07) for overall mortality. In conclusion; our study showed that despite advanced diagnostic methods and antifungals, mortality remained high, sinus involvement was the most frequent involvement, surgical debridement increased survival, but increasing age was associated with poor prognosis.\n                  <\/jats:p>","DOI":"10.1007\/s11046-026-01073-6","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T01:30:24Z","timestamp":1777426224000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Retrospective Evaluation of Mucormycosis Cases at a Tertiary Care Center Between 2000 and 2020 in T\u00fcrkiye"],"prefix":"10.1007","volume":"191","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7415-3339","authenticated-orcid":false,"given":"Hazel","family":"\u00d6zt\u00fcrk Belik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6635-5416","authenticated-orcid":false,"given":"Yasemin","family":"Heper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7380-2501","authenticated-orcid":false,"given":"Esra","family":"Kazak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3894-1231","authenticated-orcid":false,"given":"Emel","family":"Y\u0131lmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4803-8206","authenticated-orcid":false,"given":"Beyza","family":"Ener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7530-1279","authenticated-orcid":false,"given":"Halis","family":"Akal\u0131n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"issue":"12","key":"1073_CR1","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1111\/j.1469-0691.2010.03456.x","volume":"17","author":"A Skiada","year":"2011","unstructured":"Skiada A, Pagano L, Groll A, Zimmerli S, Dupont B, Lagrou K, et al. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect. 2011;17(12):1859\u201367. https:\/\/doi.org\/10.1111\/j.1469-0691.2010.03456.x.","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"1073_CR2","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1128\/CMR.18.3.556-569.2005","volume":"18","author":"B Spellberg","year":"2005","unstructured":"Spellberg B, Edwards J Jr, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev. 2005;18(3):556\u201369. https:\/\/doi.org\/10.1128\/CMR.18.3.556-569.2005.","journal-title":"Clin Microbiol Rev"},{"issue":"Suppl 1","key":"1073_CR3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/j.1470-9465.2004.00843.x","volume":"10","author":"RM Prabhu","year":"2004","unstructured":"Prabhu RM, Patel R. Mucormycosis and entomophthoramycosis: a review of the clinical manifestations, diagnosis and treatment. Clin Microbiol Infect. 2004;10(Suppl 1):31\u201347. https:\/\/doi.org\/10.1111\/j.1470-9465.2004.00843.x.","journal-title":"Clin Microbiol Infect"},{"issue":"Suppl 1","key":"1073_CR4","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1093\/cid\/cir866","volume":"54","author":"G Petrikkos","year":"2012","unstructured":"Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis. 2012;54(Suppl 1):S23-34. https:\/\/doi.org\/10.1093\/cid\/cir866.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"1073_CR5","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.3201\/eid1509.090334","volume":"15","author":"D Bitar","year":"2009","unstructured":"Bitar D, Van Cauteren D, Lanternier F, Dannaoui E, Che D, Dromer F, et al. Increasing incidence of zygomycosis (mucormycosis), France, 1997-2006. Emerg Infect Dis. 2009;15(9):1395\u2013401. https:\/\/doi.org\/10.3201\/eid1509.090334.","journal-title":"Emerg Infect Dis"},{"issue":"12","key":"1073_CR6","doi-asserted-by":"publisher","first-page":"e405","DOI":"10.1016\/S1473-3099(19)30312-3","volume":"19","author":"OA Cornely","year":"2019","unstructured":"Cornely OA, Alastruey-Izquierdo A, Arenz D, Chen SCA, Dannaoui E, Hochhegger B, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis. 2019;19(12):e405\u201321. https:\/\/doi.org\/10.1016\/S1473-3099(19)30312-3.","journal-title":"Lancet Infect Dis"},{"key":"1073_CR7","doi-asserted-by":"publisher","first-page":"101010","DOI":"10.1016\/j.lanepe.2024.101010","volume":"45","author":"L Gouzien","year":"2024","unstructured":"Gouzien L, Che D, Cassaing S, Lortholary O, Letscher-Bru V, Paccoud O, et al. Epidemiology and prognostic factors of mucormycosis in France (2012-2022): a cross-sectional study nested in a prospective surveillance programme. Lancet Reg Health Eur. 2024;45:101010. https:\/\/doi.org\/10.1016\/j.lanepe.2024.101010.","journal-title":"Lancet Reg Health Eur"},{"issue":"9","key":"1073_CR8","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1177\/1060028016655425","volume":"50","author":"TT Riley","year":"2016","unstructured":"Riley TT, Muzny CA, Swiatlo E, Legendre DP. Breaking the mold: a review of mucormycosis and current pharmacological treatment options. Ann Pharmacother. 2016;50(9):747\u201357. https:\/\/doi.org\/10.1177\/1060028016655425.","journal-title":"Ann Pharmacother"},{"key":"1073_CR9","unstructured":"World Health Organization (WHO). Mucormycosis. https:\/\/www.who.int\/india\/home\/emergencies\/coronavirus-disease-(covid-19)\/mucormycosis. Accessed 20 Mar 2026."},{"key":"1073_CR10","first-page":"3119","volume-title":"Mandell, Douglas, and Bennett\u2019s Principles and Practice of Infectious Diseases","author":"DP Kontoyiannis","year":"2025","unstructured":"Kontoyiannis DP, Lewis RE. Agents of Mucormycosis and Entomophthoramycosis. In: Blase MJ, Cohen JI, Holland SM, editors. Mandell, Douglas, and Bennett\u2019s Principles and Practice of Infectious Diseases. Philadelphia: Elsevier; 2025. p. 3119\u201332."},{"issue":"2","key":"1073_CR11","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1128\/CMR.13.2.236","volume":"13","author":"JA Ribes","year":"2000","unstructured":"Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev. 2000;13(2):236\u2013301. https:\/\/doi.org\/10.1128\/CMR.13.2.236.","journal-title":"Clin Microbiol Rev"},{"issue":"5","key":"1073_CR12","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1086\/432579","volume":"41","author":"MM Roden","year":"2005","unstructured":"Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41(5):634\u201353. https:\/\/doi.org\/10.1086\/432579.","journal-title":"Clin Infect Dis"},{"issue":"Suppl 3","key":"1073_CR13","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/myc.12243","volume":"57","author":"A Chakrabarti","year":"2014","unstructured":"Chakrabarti A, Singh R. Mucormycosis in India: unique features. Mycoses. 2014;57(Suppl 3):85\u201390. https:\/\/doi.org\/10.1111\/myc.12243.","journal-title":"Mycoses"},{"issue":"1","key":"1073_CR14","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.cmi.2018.07.011","volume":"25","author":"W Jeong","year":"2019","unstructured":"Jeong W, Keighley C, Wolfe R, Lee WL, Slavin MA, Kong DCM, et al. The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports. Clin Microbiol Infect. 2019;25(1):26\u201334. https:\/\/doi.org\/10.1016\/j.cmi.2018.07.011.","journal-title":"Clin Microbiol Infect"},{"issue":"7","key":"1073_CR15","doi-asserted-by":"publisher","first-page":"944.e9","DOI":"10.1016\/j.cmi.2019.11.021","volume":"26","author":"A Patel","year":"2020","unstructured":"Patel A, Kaur H, Xess I, Michael JS, Savio J, Rudramurthy S, et al. A multicentre observational study on the epidemiology, risk factors, management and outcomes of mucormycosis in India. Clin Microbiol Infect. 2020;26(7):944.e9-944.e15. https:\/\/doi.org\/10.1016\/j.cmi.2019.11.021.","journal-title":"Clin Microbiol Infect"},{"issue":"9462","key":"1073_CR16","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/S0140-6736(05)71046-1","volume":"365","author":"D Andresen","year":"2005","unstructured":"Andresen D, Donaldson A, Choo L, Knox A, Klaassen M, Ursic C, et al. Multifocal cutaneous mucormycosis complicating polymicrobial wound infections in a tsunami survivor from Sri Lanka. Lancet. 2005;365(9462):876\u20138. https:\/\/doi.org\/10.1016\/S0140-6736(05)71046-1.","journal-title":"Lancet"},{"issue":"23","key":"1073_CR17","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1056\/NEJMoa1204781","volume":"367","author":"R Neblett Fanfair","year":"2012","unstructured":"Neblett Fanfair R, Benedict K, Bos J, Bennett SD, Lo YC, Adebanjo T, et al. Necrotizing cutaneous mucormycosis after a tornado in Joplin, Missouri, in 2011. N Engl J Med. 2012;367(23):2214\u201325. https:\/\/doi.org\/10.1056\/NEJMoa1204781.","journal-title":"N Engl J Med"},{"issue":"11","key":"1073_CR18","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1093\/cid\/cis749","volume":"55","author":"T Warkentien","year":"2012","unstructured":"Warkentien T, Rodriguez C, Lloyd B, Wells J, Weintrob A, Dunne JR, et al. Invasive mold infections following combat-related injuries. Clin Infect Dis. 2012;55(11):1441\u20139. https:\/\/doi.org\/10.1093\/cid\/cis749.","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"1073_CR19","doi-asserted-by":"publisher","first-page":"S44","DOI":"10.1093\/cid\/cir867","volume":"54","author":"B Rammaert","year":"2012","unstructured":"Rammaert B, Lanternier F, Zahar JR, Dannaoui E, Bougnoux ME, Lecuit M, et al. Healthcare-associated mucormycosis. Clin Infect Dis. 2012;54(Suppl 1):S44-54. https:\/\/doi.org\/10.1093\/cid\/cir867.","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"1073_CR20","doi-asserted-by":"publisher","first-page":"S93","DOI":"10.1093\/mmy\/myx101","volume":"56","author":"A Skiada","year":"2018","unstructured":"Skiada A, Lass-Floerl C, Klimko N, Ibrahim A, Roilides E, Petrikkos G. Challenges in the diagnosis and treatment of mucormycosis. Med Mycol. 2018;56(Suppl 1):S93-101. https:\/\/doi.org\/10.1093\/mmy\/myx101.","journal-title":"Med Mycol"},{"issue":"2","key":"1073_CR21","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1128\/IAI.73.2.778-783.2005","volume":"73","author":"AS Ibrahim","year":"2005","unstructured":"Ibrahim AS, Spellberg B, Avanessian V, Fu Y, Edwards JE Jr. Rhizopus oryzae adheres to, is phagocytosed by, and damages endothelial cells in vitro. Infect Immun. 2005;73(2):778\u201383. https:\/\/doi.org\/10.1128\/IAI.73.2.778-783.2005.","journal-title":"Infect Immun"},{"issue":"3","key":"1073_CR22","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1179\/joc.2009.21.3.272","volume":"21","author":"PE Verweij","year":"2009","unstructured":"Verweij PE, Gonz\u00e1lez GM, Wiederhold NP, Lass-Fl\u00f6rl C, Warn P, Heep M, et al. In vitro antifungal activity of isavuconazole against 345 Mucorales isolates collected at study centers in eight countries. J Chemother. 2009;21(3):272\u201381. https:\/\/doi.org\/10.1179\/joc.2009.21.3.272.","journal-title":"J Chemother"},{"key":"1073_CR23","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1128\/jcm.06133-11","volume":"50","author":"RG Vitale","year":"2012","unstructured":"Vitale RG, de Hoog GS, Schwarz P, et al. Antifungal susceptibility and phylogeny of opportunistic members of the order Mucorales. J Clin Microbiol. 2012;50:66\u201375. https:\/\/doi.org\/10.1128\/jcm.06133-11.","journal-title":"J Clin Microbiol"},{"issue":"3","key":"1073_CR24","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3324\/haematol.2016.152900","volume":"102","author":"F Tissot","year":"2017","unstructured":"Tissot F, Agrawal S, Pagano L, et al. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica. 2017;102(3):433\u201344.","journal-title":"Haematologica"},{"issue":"6","key":"1073_CR25","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","volume":"71","author":"JP Donnelly","year":"2020","unstructured":"Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE, et al. Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis. 2020;71(6):1367\u201376. https:\/\/doi.org\/10.1093\/cid\/ciz1008.","journal-title":"Clin Infect Dis"},{"issue":"Suppl 5","key":"1073_CR26","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/j.1469-0691.2009.02981.x","volume":"15","author":"E Roilides","year":"2009","unstructured":"Roilides E, Zaoutis TE, Walsh TJ. Invasive zygomycosis in neonates and children. Clin Microbiol Infect. 2009;15(Suppl 5):50\u20134. https:\/\/doi.org\/10.1111\/j.1469-0691.2009.02981.x.","journal-title":"Clin Microbiol Infect"},{"issue":"8","key":"1073_CR27","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1097\/INF.0b013e318062115c","volume":"26","author":"TE Zaoutis","year":"2007","unstructured":"Zaoutis TE, Roilides E, Chiou CC, Buchanan WL, Knudsen TA, Sarkisova TA, et al. Zygomycosis in children: a systematic review and analysis of reported cases. Pediatr Infect Dis J. 2007;26(8):723\u20137. https:\/\/doi.org\/10.1097\/INF.0b013e318062115c.","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"1073_CR28","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1017\/S0950268805004930","volume":"134","author":"MR Al-Ajam","year":"2006","unstructured":"Al-Ajam MR, Bizri AR, Mokhbat J, Weedon J, Lutwick L. Mucormycosis in the Eastern Mediterranean: a seasonal disease. Epidemiol Infect. 2006;134(2):341\u20136. https:\/\/doi.org\/10.1017\/S0950268805004930.","journal-title":"Epidemiol Infect"},{"issue":"1","key":"1073_CR29","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1067\/mhn.2002.126587","volume":"127","author":"YP Talmi","year":"2002","unstructured":"Talmi YP, Goldschmied-Reouven A, Bakon M, Barshack I, Wolf M, Horowitz Z, et al. Rhino-Orbital and Rhino-Orbito-Cerebral Mcormycosis. Otolaryngol Head Neck Surg. 2002;127(1):22\u201331. https:\/\/doi.org\/10.1067\/mhn.2002.126587.","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"1","key":"1073_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF00437092","volume":"133","author":"MFJ Caba\u00f1es","year":"1996","unstructured":"Caba\u00f1es MFJ, Abarca ML, Bragulat MR, Castell\u00e0 G. Seasonal study of the fungal biota of the fur of dogs. Mycopathologia. 1996;133(1):1\u20137. https:\/\/doi.org\/10.1007\/BF00437092.","journal-title":"Mycopathologia"},{"key":"1073_CR31","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s10096-025-05397-x","volume":"45","author":"Y \u00c7i\u00e7ek","year":"2026","unstructured":"\u00c7i\u00e7ek Y, Dumlu R, Ko\u00e7ak M, Pirdal BZ, \u00c7elik M, Salto\u011flu N, et al. Epidemiological profile and clinical outcomes of patients with mucormycosis: the multicenter retromucor study from T\u00fcrkiye (2004\u20132024). Eur J Clin Microbiol Infect Dis. 2026;45:537\u201355. https:\/\/doi.org\/10.1007\/s10096-025-05397-x.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"4","key":"1073_CR32","doi-asserted-by":"publisher","DOI":"10.1007\/s11046-025-00954-6","volume":"190","author":"A Skiada","year":"2025","unstructured":"Skiada A, Drogari-Apiranthitou M, Roilides E, Chander J, Khostelidi S, Klimko N, et al. A global analysis of cases of mucormycosis recorded in the European Confederation of Medical Mycology \/ International Society for Human and Animal Mycology (ECMM \/ ISHAM) Zygomyco.net Registry from 2009 to 2022. Mycopathologia. 2025;190(4):53. https:\/\/doi.org\/10.1007\/s11046-025-00954-6.","journal-title":"Mycopathologia"},{"key":"1073_CR33","doi-asserted-by":"publisher","first-page":"708","DOI":"10.5578\/mb.5836","volume":"47","author":"AN Zeka","year":"2013","unstructured":"Zeka AN, Ta\u015fbakan M, Pulluk\u00e7u H, Sipahi OR, Yamazhan T, Arda B. T\u00fcrkiye\u2019den Bildirilen Zigomikoz Olgular\u0131n\u0131n Havuz Analiz Y\u00f6ntemi ile De\u011ferlendirilmesi. Mikrobiyol Bul. 2013;47:708\u201316.","journal-title":"Mikrobiyol Bul"},{"issue":"1","key":"1073_CR34","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3906\/sag-1409-137","volume":"46","author":"S K\u00f6m\u00fcr","year":"2016","unstructured":"K\u00f6m\u00fcr S, I\u0307nal AS, Kurtaran B, Ulu A, U\u011fuz A, Aksu HSZ, et al. Mucormycosis: a 10-year experience at a tertiary care center in Turkey. Turk J Med Sci. 2016;46(1):58\u201362. https:\/\/doi.org\/10.3906\/sag-1409-137.","journal-title":"Turk J Med Sci"},{"issue":"Suppl 1","key":"1073_CR35","doi-asserted-by":"publisher","first-page":"S55","DOI":"10.1093\/cid\/cir868","volume":"54","author":"TJ Walsh","year":"2012","unstructured":"Walsh TJ, Gamaletsou MN, McGinnis MR, Hayden RT, Kontoyiannis DP. Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis). Clin Infect Dis. 2012;54(Suppl 1):S55\u201360. https:\/\/doi.org\/10.1093\/cid\/cir868.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"1073_CR36","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1056\/NEJM200402263500923","volume":"350","author":"FM Marty","year":"2004","unstructured":"Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med. 2004;350(9):950\u20132. https:\/\/doi.org\/10.1056\/NEJM200402263500923.","journal-title":"N Engl J Med"},{"issue":"9","key":"1073_CR37","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1086\/597615","volume":"199","author":"GA Lamaris","year":"2009","unstructured":"Lamaris GA, Ben-Ami R, Lewis RE, Chamilos G, Samonis G, Kontoyiannis DP. Increased virulence of Zygomycetes organisms following exposure to voriconazole: a study involving fly and murine models of zygomycosis. J Infect Dis. 2009;199(9):1399\u2013406. https:\/\/doi.org\/10.1086\/597615.","journal-title":"J Infect Dis"},{"issue":"4","key":"1073_CR38","doi-asserted-by":"publisher","first-page":"348","DOI":"10.4161\/viru.2.4.17074","volume":"2","author":"RE Lewis","year":"2011","unstructured":"Lewis RE, Liao G, Wang W, Prince RA, Kontoyiannis DP. Voriconazole pre-exposure selects for breakthrough mucormycosis in a mixed model of Aspergillus fumigatus-Rhizopus oryzae pulmonary infection. Virulence. 2011;2(4):348\u201355. https:\/\/doi.org\/10.4161\/viru.2.4.17074.","journal-title":"Virulence"},{"issue":"4","key":"1073_CR39","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1086\/590004","volume":"47","author":"G Chamilos","year":"2008","unstructured":"Chamilos G, Lewis RE, Kontoyiannis DP. Delaying Amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis. 2008;47(4):503\u20139. https:\/\/doi.org\/10.1086\/590004.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"1073_CR40","doi-asserted-by":"publisher","first-page":"3343","DOI":"10.1128\/aac.47.10.3343-3344.2003","volume":"47","author":"AS Ibrahim","year":"2003","unstructured":"Ibrahim AS, Avanessian V, Spellberg B, Edwards JE Jr. Liposomal Amphotericin B, and not Amphotericin B deoxycholate, improves survival of diabetic mice infected with Rhizopus oryzae. Antimicrob Agents Chemother. 2003;47(10):3343\u20134. https:\/\/doi.org\/10.1128\/aac.47.10.3343-3344.2003.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"1073_CR41","doi-asserted-by":"publisher","first-page":"3116","DOI":"10.1093\/jac\/dkv236","volume":"70","author":"F Lanternier","year":"2015","unstructured":"Lanternier F, Poiree S, Elie C, Garcia-Hermoso D, Bakouboula P, Sitbon K, et al. Prospective pilot study of high-dose (10 mg\/kg\/day) liposomal Amphotericin B (L-AMB) for the initial treatment of mucormycosis. J Antimicrob Chemother. 2015;70(11):3116\u201323. https:\/\/doi.org\/10.1093\/jac\/dkv236.","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"1073_CR42","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","volume":"16","author":"FM Marty","year":"2016","unstructured":"Marty FM, Ostrosky-Zeichner L, Cornely OA, Mullane KM, Perfect JR, Thompson GR 3rd, et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis. 2016;16(7):828\u201337. https:\/\/doi.org\/10.1016\/S1473-3099(16)00071-2.","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"1073_CR43","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1007\/s40121-024-01064-4","volume":"13","author":"D Neofytos","year":"2024","unstructured":"Neofytos D, Pagliuca A, Houghton K, Broughton E, de Figueiredo Valente MLN, Jiang L, et al. Effectiveness, safety, and patterns of real-world isavuconazole use in Europe (2015-2019). Infect Dis Ther. 2024;13(12):2527\u201343. https:\/\/doi.org\/10.1007\/s40121-024-01064-4.","journal-title":"Infect Dis Ther"},{"issue":"6","key":"1073_CR44","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s11046-021-00584-8","volume":"186","author":"V Muthu","year":"2021","unstructured":"Muthu V, Rudramurty SM, Chakrabarti A, Agarwal R, et al. Epidemiology and pathophysiology of COVID-19-associated mucormycosis: India versus the rest of the world. Mycopathologia. 2021;186(6):739\u201354. https:\/\/doi.org\/10.1007\/s11046-021-00584-8.","journal-title":"Mycopathologia"},{"issue":"6","key":"1073_CR45","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.cmi.2023.03.008","volume":"29","author":"L \u00d6zbek","year":"2023","unstructured":"\u00d6zbek L, Top\u00e7u U, Manay M, Esen BH, Bektas SN, Ayd\u0131n S, et al. COVID-19\u2013associated mucormycosis: a systematic review and meta-analysis of 958 cases. Clin Microbiol Infect. 2023;29(6):722\u201331. https:\/\/doi.org\/10.1016\/j.cmi.2023.03.008.","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"1073_CR46","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3201\/eid2901.220926","volume":"29","author":"V Muthu","year":"2023","unstructured":"Muthu V, Agarwal R, Rudramurthy SM, Thangaraju D, Shevkani MR, Patel AK, et al. Multicenter case\u2013control study of COVID-19\u2013associated mucormycosis outbreak, India. Emerg Infect Dis. 2023;29(1):8\u201319. https:\/\/doi.org\/10.3201\/eid2901.220926.","journal-title":"Emerg Infect Dis"},{"issue":"15","key":"1073_CR47","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1007\/s40265-021-01611-0","volume":"81","author":"M Hoenigl","year":"2021","unstructured":"Hoenigl M, Sprute R, Egger M, Arestehfar A, Cornely OA, Krause R, et al. The antifungal pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin. Drugs. 2021;81(15):1703\u201329. https:\/\/doi.org\/10.1007\/s40265-021-01611-0.","journal-title":"Drugs"}],"container-title":["Mycopathologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11046-026-01073-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11046-026-01073-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11046-026-01073-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T07:18:49Z","timestamp":1781075929000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11046-026-01073-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1073"],"URL":"https:\/\/doi.org\/10.1007\/s11046-026-01073-6","relation":{},"ISSN":["0301-486X","1573-0832"],"issn-type":[{"value":"0301-486X","type":"print"},{"value":"1573-0832","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"assertion":[{"value":"15 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The affiliation details for Hazel \u00d6zt\u00fcrk Belik and Beyza Ener have been corrected.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Bursa Uludag University (Approval date: July 28, 2021\/ Approval number: 2021\u201410\/5).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}],"article-number":"49"}}